Geron Corporation (GERN)
3.00
0.04 (1.35%)
At close: Jan 28, 2025, 1:20 PM
Company Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation
| Country | United States |
| IPO Date | Jul 31, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | Dr. John A. Scarlett M.D. |
Contact Details
Address: 919 East Hillsdale Boulevard Foster City, California United States | |
| Website | https://www.geron.com |
Stock Details
| Ticker Symbol | GERN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886744 |
| CUSIP Number | 374163103 |
| ISIN Number | US3741631036 |
| Employer ID | 75-2287752 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John A. Scarlett M.D. | Chairman of the Board, President & Chief Executive Officer |
| Dr. Andrew J. Grethlein Ph.D. | Executive Vice President & Chief Operating Officer |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer |
| Scott Samuels | Executive Vice President, Chief Legal Officer & Secretary |
| Shannon T. Odam | Senior Vice President & Chief People Officer |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications |
| Dr. Faye Feller M.D. | Executive Vice President & Chief Medical Officer |
| Edward E. Koval | Executive Vice President & Chief Business Officer |
| James Ziegler M.B.A. | Executive Vice President & Chief Commercial Officer |
| Melissa A. Kelly Behrs | Executive Vice President of Business Operations & Chief Alliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | S-8 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 3 | Filing |
| Nov 12, 2024 | 4 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |